<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03704844</url>
  </required_header>
  <id_info>
    <org_study_id>7148</org_study_id>
    <nct_id>NCT03704844</nct_id>
  </id_info>
  <brief_title>Evaluation of the Renal Congestion, Perfusion and Function Before and After Diuretic Treatment in the ICU</brief_title>
  <acronym>ECHOFURO</acronym>
  <official_title>Evaluation of the Renal Congestion, Perfusion and Function Before and After Diuretic Treatment in the ICU</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Renal congestion is a pathological state that can lead to acute kidney failure. Furosemide is
      known to lower renal congestion by its diuretic effect.

      The aim of this trial is to study the reversibility of kidney congestion under diuretic
      therapy and assess through echodoppler parameters if it can improve renal perfusion and
      function in congestive ICU patients.

      It could in fine lead to a better identification of patients that could benefit from diuretic
      therapy in the ICU.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2018</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Effects of diuretics</measure>
    <time_frame>24 hours</time_frame>
    <description>Evaluation of renal perfusion diuretic treatment by measuring the renal resistance index and the renal venous impedance index.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Renal Congestion</condition>
  <arm_group>
    <arm_group_label>Patients with renal congestion</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients without renal congestion</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>non applicable</intervention_name>
    <description>non applicable</description>
    <arm_group_label>Patients with renal congestion</arm_group_label>
    <arm_group_label>Patients without renal congestion</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        ICU patients under treatment by furosemide
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patient hospitalized in ICU

          -  under furosemide treatment

        Exclusion Criteria:

          -  participation refusal

          -  uncontrolled shock (MAP&lt;65mmHg)

          -  abdominal compartment syndrome

          -  diuretic administration in the 6 hours prior to inclusion

          -  renal replacement therapy or stage 4-5 chronic kidney disease

          -  atrial fibrillation

          -  no monitoring of CVP / invasive arterial pressure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHU Amiens-Picardie</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ousama ABOU ARAB</last_name>
      <phone>+33 6 22 66 24 84</phone>
      <email>abouao@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ousama ABOU ARAB</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pierre Grégoire GUINOT</last_name>
      <phone>+33 645871619</phone>
      <email>guinotpierregregoire@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Pierre Grégoire GUINOT</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Les Hôpitaux Universitaires de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thibaut WIPF</last_name>
      <phone>+33 3 69 55 12 64</phone>
      <email>thibaut.wipf@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Thibaut WIPF</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paul-Michel MERTES</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gharib AJOB</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>July 30, 2018</study_first_submitted>
  <study_first_submitted_qc>October 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 15, 2018</study_first_posted>
  <last_update_submitted>April 29, 2019</last_update_submitted>
  <last_update_submitted_qc>April 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

